A real-life, pilot study to evaluate the efficacy and safety of sofosbuvir plus simeprevir combination without ribavirin for the re-treatment of patients with chronic hepatitis C virus genotype 1 or 4 infection and who previously failed a daclatasvir-containing regimen

Trial Profile

A real-life, pilot study to evaluate the efficacy and safety of sofosbuvir plus simeprevir combination without ribavirin for the re-treatment of patients with chronic hepatitis C virus genotype 1 or 4 infection and who previously failed a daclatasvir-containing regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Simeprevir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 12 Feb 2016 New trial record
    • 08 Feb 2016 Results published in the Hepatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top